Please visit the “We Cann Mix – An Experience in Diversity” at https://www.wecannmix.com

In addition to providing cannabis patients with a wealth of knowledge, guidance, and other resources, Cannabis Science and The Joey Network are actively working with the CanI?Liv Foundation to provide financial aid to eligible cannabis patients in need of assistance.

“We are thrilled to have the opportunity to once again work with Mieko Hester-Perez to help get life-changing treatments in the hands of more hopeful patients,” said CEO Raymond C. Dabney. “Enhancing our network will allow us to progress with our mission by treating more patients, more efficiently, and more effectively. Ms. Perez has garnered much support and is considered an unfettered voice for cannabis treating Autism. She was able to bridge the gap between politicians, physicians, pharmaceuticals, and hospitals to continue the conversation on the treatment of Autism with medical cannabis. We are very proud of her!”

About The Joey Network

The Joey Network is the first cannabis and autism-centered APP made available for patients and families worldwide. Ms. Perez continues sharing the success she and her son have had for the treatment of Autism.

About The CanI?Liv Foundation

The CanI?Liv Foundation, an organization for the good of cannabis patients. Founded in 2013, CanI?Liv organized in an effort to ease financial burden, to advocate for legitimacy, and to aid with the overall well-being of cannabis patients by supplementing the cost of medication, emergency assistance, and offering patient support.

To learn more about the powerful work CanI?Liv is doing, visit their website at https://www.can-i-liv.org/

About Cannabis Science, Inc.

Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.

Forward-Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as “anticipate,” “seek,” intend,” “believe,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a ‘safe harbor’ for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward- looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company are detailed from time to time in the company’s reports filed with the Securities and Exchange Commission.

Image Available: https://www2.marketwire.com/mw/frame_mw?attachid=3031265